Microbiotica

About Microbiotica

Microbiotica is a biotechnology startup that specializes in microbiome analysis, a field that studies the ecosystem of bacteria, viruses, and fungi that live in our bodies, particularly in our gut. The company has a unique advantage in this field due to its decade-long investment in the Wellcome Sanger Institute, which has given it unparalleled capabilities in microbiome analysis and bacterial culturing.

Microbiotica operates in the healthcare and biotechnology market, serving clients such as pharmaceutical companies, research institutions, and hospitals. Its business model revolves around developing and commercializing its proprietary technology and products. These include a world-leading microbiome Culture Collection, a Reference Genome Database, and advanced bioinformatics tools.

The company also develops clinically-derived products such as Live Bacterial Therapeutics and Biomarkers, which are used in the treatment of various diseases including Inflammatory Bowel Disease (IBD), Immuno-oncology, and Gut Epithelial Barrier Repair. These products are developed through collaborations with global partners like MSD (Merck & Co., Inc.), Cancer Research UK, Cambridge University Hospitals, and the University of Adelaide.

Microbiotica generates revenue through the sale of its products and services, as well as through strategic partnerships and collaborations. For instance, it recently announced a clinical trial collaboration with MSD to evaluate a new therapy for melanoma.

In summary, Microbiotica is a pioneer in the field of microbiome analysis, leveraging its unique capabilities to develop innovative products and services that have the potential to revolutionize healthcare and biotechnology.